86. 肺動脈性肺高血圧症 Pulmonary arterial hypertension Clinical trials / Disease details
臨床試験数 : 1,181 / 薬物数 : 701 - (DrugBank : 126) / 標的遺伝子数 : 105 - 標的パスウェイ数 : 192
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | JPRN-JapicCTI-101370 | 10/12/2010 | 09/12/2010 | Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients | A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Intervention name : Sitaxentan sodium INN of the intervention : Sitaxentan Dosage And administration of the intervention : 100 mg, once daily Control intervention name : null | Pfizer Japan Inc. | NULL | 16 | 80 | BOTH | 35 | Phase 3 | NULL | |
| 2 | NCT01210443 (ClinicalTrials.gov) | November 2010 | 11/8/2010 | Long-Term Open-Label, Safety Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients | A Phase 3, Multi-Center, Open Label Study To Evaluate The Long-Term Safety Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension | Hypertension, Pulmonary | Drug: Sitaxentan | Pfizer | NULL | Terminated | 16 Years | 80 Years | All | 2 | Phase 3 | Japan |
| 3 | JPRN-JapicCTI-101369 | 20/8/2010 | 09/12/2010 | A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients | A Phase 3, Multi-Center, Open Label Study to Investigate Safety and efficacy of Sitaxentan THERAPY in japanese Subjects with Pulmonary Arterial Hypertension | Pulmonary Arterial Hypertension | Intervention name : Sitaxentan sodium INN of the intervention : Sitaxentan Dosage And administration of the intervention : 100 mg, once daily Control intervention name : null | Pfizer Japan Inc. | NULL | 16 | 80 | BOTH | 35 | Phase 3 | NULL | |
| 4 | NCT01204853 (ClinicalTrials.gov) | August 2010 | 6/8/2010 | A 12 Week Safety And Efficacy Study Of Sitaxentan Sodium In Japanese Pulmonary Arterial Hypertension Patients | A Phase 3, Multi-Center, Open Label Study To Evaluate The Safety And Efficacy Of Sitaxentan Sodium In Japanese Subjects With Pulmonary Arterial Hypertension | Hypertension, Pulmonary | Drug: Sitaxentan | Pfizer | NULL | Terminated | 16 Years | 80 Years | All | 2 | Phase 3 | Japan |
| 5 | NCT00995566 (ClinicalTrials.gov) | April 2010 | 17/9/2009 | A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin | Thelin (Sitaxentan Sodium) Patient Safety Registry A Non-Interventional, Patient Registry For The Collection Of Pre-Defined Safety Data In Patients Prescribed Thelin | Pulmonary Arterial Hypertension | Drug: Sitaxentan sodium | Pfizer | NULL | Terminated | 18 Years | N/A | All | 54 | N/A | Belgium;France;Germany;Sweden |
| 6 | NCT01445873 (ClinicalTrials.gov) | December 1, 2009 | 30/9/2011 | Pilot Chart Review Study Of Sitaxentan Sodium (Thelin) In Patients With Pulmonary Arterial Hypertension (PAH) | NON-INTERVENTIONAL (NI) DRUG STUDY PROTOCOL: THREE-COUNTRY PILOT STUDY FOR RETROSPECTIVE CHART REVIEW OF EFFECTIVENESS OF THELIN® (SITAXSENTAN) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION (PAH) | Pulmonary Arterial Hypertension | Drug: Sitaxentan sodium | Pfizer | NULL | Completed | 18 Years | N/A | All | 36 | NULL | |
| 7 | NCT00080457 (ClinicalTrials.gov) | May 2003 | 1/4/2004 | Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension | A Phase 3, Randomized, Double-Blind, Placebo-Controlled Safety and Efficacy Study of Sitaxsentan Sodium (Thelin™) Treatment With an Open-Label Bosentan Arm in Patients With Pulmonary Arterial Hypertension (PAH) | Pulmonary Hypertension | Drug: sitaxsentan sodium | Encysive Pharmaceuticals | NULL | Completed | 12 Years | 75 Years | Both | 240 | Phase 3 | United States |